IL13Ra2 targeted T-cell therapy for glioma

IL13Ra2靶向T细胞治疗胶质瘤

• 批准号: 8805489
• 负责人: Irina V Balyasnikova
• 金额: $ 40.86万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-30 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8805489
• 关键词: Affinity; Animal Model; Animals; Antigen Receptors; Binding; Biological Assay; Blood - brain barrier anatomy; Brain; Brain Neoplasms; CD28 Antigens; CD28 gene; CD3 Antigens; Cells; Clinical; Coculture Techniques; Complement; Cytotoxic T-Lymphocytes; Data; Development; Diagnosis; ERBB2 gene; Engineering; Exposure to; Foundations; Frequencies; Future; Generations; Glioblastoma; Glioma; Grant; Immune; Immune system; Immunologic Techniques; Immunosuppressive Agents; Immunotherapy; In Vitro; Information Systems; Interleukin-13; Malignant Neoplasms; Modeling; Monoclonal Antibodies; Mus; Nature; Neoplasm Metastasis; Normal tissue morphology; Operative Surgical Procedures; Patients; Pharmaceutical Preparations; Phase I Clinical Trials; Population; Pre-Clinical Model; Preclinical Testing; Primary Brain Neoplasms; Primary Neoplasm; Radiation therapy; Research Personnel; Signal Transduction; Specificity; T cell therapy; T-Cell Receptor; T-Lymphocyte; Testing; Therapeutic; Toxic effect; Transmembrane Domain; Tumor Antigens; Xenograft Model; bioluminescence imaging; cancer cell; combinatorial; cytokine; cytotoxic; cytotoxicity; design; epidermal growth factor receptor VIII; human IL13RA1 protein; human disease; in vivo; innovation; killings; neoplastic cell; pre-clinical; public health relevance; receptor; research study; retroviral transduction; tool; tumor; tumor microenvironment

 DESCRIPTION (provided by applicant): Glioblastoma multiform (GBM) is the most common of all primary brain tumors with limited therapeutic options due to the diffusely infiltrative nature f the tumor and the presence of the blood brain barrier (BBB). Given an ability of T cells to penetrate the BBB and infiltrate tumors, T cells expressing chimeric antigen receptors (CARs) targeting tumor specific antigens have the potential to serve as a unique cytotoxic tool specifically targeting primary tumors or metastases that localize to the brain. IL13Rα2, the high affinity IL13 receptor is a promising candidate for GBM-targeted therapy since it is expressed at a high frequency in GBM, but not in normal tissues. The majority of prior IL13Rα2-targeted approaches take advantage of IL13 mutinies, which also recognize IL13Rα1-positive target cells, raising concerns of 'on target/off cancer' toxicities. We have therefore developed a high affinity IL13Rα2-specific monoclonal antibody (MAb) that does not cross-react with IL13Rα1. Importantly, our preliminary results indicate that T cells expressing CARs that contain a single chain variable fragment (scFv) of IL13Rα2-specific MAb (IL13Rα2-CAR T cells), are specific for IL13Rα2 and do not recognize or kill target cells expressing IL13Rα1. In this proposal we now hypothesize that IL13Rα2-CAR T cells will have potent anti-glioma activity in preclinical GBM models. CAR T cells have been primarily evaluated in xenograft models that lack salient features of GBMs; most importantly, they do not recapitulate their immunosuppressive tumor microenvironment, limiting preclinical testing and future development of CAR T cells. We hypothesize that these limitations can be overcome by adapting immune competent GBM models, which closely mimics human disease for in vivo testing of IL13Rα2-CAR T cells. Our hypotheses will be evaluated in two interrelated Aims. In Aim 1 we will construct a panel of IL13Rα2-CARs that contain our new scFvIL13Rα2 as an ectodomain, a short or long hinge, a transmembrane domain, and endodomains that contain a CD3ζ signaling domain, and signaling domains derived from co-stimulatory molecules (CD28.ζ, CD28.CD134.ζ, or CD28.CD137. ζ). The effector function of murine T cells expressing these CARs will be evaluated in vitro using standard immunological assays. While the results of our in vitro experiments will allow us to answer questions pertinent to optimal functioning of our experimental system, these data will not be fully representing the in vivo setting. To bridge this gap, we will compare in Aim 2 optimized IL13Rα2-CARs in vivo using the GL261 and SMA-560 immune competent glioma models. We expect at the conclusion of the grant that we will have determined the optimal design of IL13Rα2-CARs and have completed the testing of IL13Rα2-CAR T cells in relevant, immune competent glioma models. While we use this data to justify the development of a Phase I clinical trial, the developed model will also be useful for future studies in which we aim to combine IL13Rα2-CAR T cells with other glioma-targeted therapies.